Immutep Profile

1.70
USD 0.02  1.16%
0%
100%

Immutep Summary

Immutep Limited (PBMD) is traded on NASDAQ General Markets in USA. It is located in Sydney, NSW and employs 31 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 46.7 M. Immutep Limited has 0 outstanding shares of which 137.1 K shares are at this time shorted by private and institutional investors with about 1.25 trading days to cover. Prima BioMed Ltd currently holds about 9.74 M in cash with (6.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41.
Check Immutep Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Key Fundamentals

Immutep Against Markets

Similar Equity Warning - PBMD

Immutep Limited was forked
  The entity Immutep Limited with a symbol PBMD was recently forked. You can potentially use Immutep Limited with a symbol IMMP from now on.

Current Ratings

Immutep 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
77 
Equity ratings for Immutep Limited are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Prima BioMed Ltd. engages in the research, development, and commercialization of medical biotechnology solutions in Australia. more
NameImmutep Limited
CEOMarc VoigtView All
Analyst Consensus
Macroaxis Advice
InstrumentUSA Stock View All
Business AddressSydney, NSW
ExchangeNASDAQ General Markets
New SymbolIMMP
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.primabiomed.com.au
61 2 8315 7003
CurrencyUSD - US Dollar

Immutep Corporate Directors

Pete Meyers Non-Executive Director, MBA
Russell Howard Non-Executive Director, Ph.D
Larisa Chisholm Director of Industry Liaison and Devel. and Director of Intellectual Property
Additionally take a look at Your Equity Center. Please also try Equity Analysis module to research over 250,000 global equities including funds, stocks and etfs to find investment opportunities.